Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended March 31, 2013 (fiscal 2013 second quarter). Financial statements are unaudited; amounts below are in millions unless noted.
Business context
Enanta is a research-focused biotechnology company with no approved products or product-sales revenue. Its programs include ABT-450, a hepatitis C (HCV) protease inhibitor developed by AbbVie; EDP-239 and other NS5A inhibitors partnered with Novartis; internally funded HCV research; and Bicyclolide antibiotics, including EDP-788, supported in part by an NIAID contract.
Financial performance and liquidity
| Metric | Three months ended March 31 | Six months ended March 31 |
|---|---|---|
| Revenue, 2013 | $1.196 | $29.055 |
| Revenue, 2012 | $36.565 | $37.306 |
| Research and development expense, 2013 | $3.704 | $8.502 |
| General and administrative expense, 2013 | $1.493 | $2.645 |
| Net income (loss), 2013 | $(3.749) | $18.208 |
| Net income (loss) attributable to common stockholders, 2013 | $(4.993) | $2.012 |
| Basic EPS attributable to common stockholders | $(2.28) | $1.21 |
- Quarterly revenue fell sharply year over year as the comparable 2012 quarter included recognition of Novartis’s $34.4 million upfront payment. Six-month 2013 revenue included $15.0 million in AbbVie milestones and $11.0 million in Novartis milestones.
- Operating expenses were $5.197 million for the quarter and $11.147 million for the six months. No gross margin is presented; product sales and related product gross profit have not begun.
- Six-month operating cash flow was $19.078 million, versus $28.153 million a year earlier. Investing activities used $13.359 million and financing activities provided $58.234 million, mainly reflecting the IPO. Cash and cash equivalents ended at $74.464 million.
- At March 31, cash, cash equivalents and marketable securities totaled approximately $121.7 million. Total assets were $125.627 million, current liabilities $4.951 million, and total liabilities $7.252 million. The company reported no debt outstanding.
- The company completed its IPO on March 26, selling 4.6 million shares at $14.00 per share. The filing reports approximately $59.9 million net of underwriting commissions in its financial discussion, while the use-of-proceeds section reports approximately $55.3 million after underwriting commissions and offering expenses; these figures use different cost deductions.
Changes, outlook and material items
- R&D expense rose 14% in the quarter and 43% over six months versus the prior-year periods, primarily due to increased early-stage discovery work. Management expected fiscal 2013 R&D expense of approximately $21 million, excluding collaborators’ development costs.
- Management believed existing cash, cash equivalents and investments would fund anticipated requirements for at least 24 months. This outlook depends on uncertain program costs, collaboration milestones and development outcomes.
- Management expects near-term revenue to remain substantially dependent on AbbVie and Novartis. Enanta cannot predict when or whether further milestones will be earned; it has not earned product royalties and may not report revenue or net income in future periods.
- AbbVie’s ABT-450 program had entered Phase 3 combination trials. Novartis funding for additional NS5A research was extended through August 2013. The AbbVie agreement offered up to $275 million in specified future regulatory milestones for the first and additional protease-inhibitor products; Novartis milestones could total up to $406 million, subject to development and sales achievements.
- The NIAID contract’s initial funding was $14.3 million for 30 months, with potential total funding of $42.7 million if options are exercised. NIAID notified Enanta of possible effects from sequestration, including not exercising options or negotiating lower prices or other terms.
- In the quarter, Enanta accrued $0.5 million for a potential license relating to patents used or possibly used in prior periods after determining the probable cost could be reasonably estimated. The filing also describes ongoing potential intellectual-property licensing needs and related litigation risk; it reports no threatened or pending litigation at quarter-end.
- Disclosure controls were assessed as effective, with no material change in internal control over financial reporting identified during the quarter.
Key investor verification points
- Track AbbVie’s and Novartis’s clinical progress, future milestone triggers, collaboration funding and termination rights; milestone revenue is irregular and not assured.
- Confirm NIAID option decisions and funding after the initial contract term, including the potential impact of sequestration.
- Review cash and investment levels against the stated 24-month runway, planned R&D spending and public-company costs.
- Clarify the IPO proceeds presentation: approximately $59.9 million after underwriting commissions versus approximately $55.3 million after total offering expenses.
- Monitor intellectual-property licensing exposure, including the accrued $0.5 million potential license cost and the separate disclosed license obligations.
- Interpret reported net income alongside common-stockholder results: preferred-stock accretion and participating-security allocations materially affected common EPS.